I’m sick to my freaking stomach reading Tulsi Gabbard’s declassified bombshells. They laid out the entire treasonous plot: weaponizing the Zelensky phone call to impeach Trump, with Rudy Giuliani squarely in their crosshairs next.
This wasn’t politics—it was a straight-up coup by corrupt deep state actors to overthrow the will of the American people.
These people belong in prison for this shit. Deeply disturbing and downright terrifying.
“We found 146,000 kids so far. Some of these kids claimed that they were raped over 600 times. I don't care who you are. If you can't stand for law enforcement to go find these kids, who are you?” @SecMullinDHS
FAUCI CAUGHT ON TAPE: "When you make it difficult for people in their lives, they lose their ideological BS and they get VACCINATED."
"You want to come to this college, buddy? You're going to get VACCINATED."
ONE WEEK LEFT TO PROSECUTE HIM.
The decision should be EASY.
I have never been treated more rudely than I was just now by @SouthwestAir I’m shaking. My band and crew have flown this airline for a long time. I’m afraid it’s time to switch. Maybe someone was having a bad morning, so I want to extend grace. But my goodness! That was crazy!
The reports about Ivermectin, Fenbendazole and Mebendazole attacking cancer cells and taking people from Stage 4 to remission is incredible! How long has big pharma known this? How lucrative is chemo? How many millions have died?
Congratulations to our graduating seniors at our FIRST in Texas State Championship. FIRST Alumni and NASA employee Allison Rich spoke to the class of 2026 about college, careers, and life beyond school.
@FIRSTinTexas The YouTube feed for the Apollo Division is having some major issues. I hope it gets fixed before the competition goes much farther. @FIRSTinTexas#Rocketeers #8114
84.4% of cancer patients taking ivermectin + mebendazole declared NO EVIDENCE OF DISEASE, TUMOR SHRINKAGE, or CANCER STABILIZATION after 6 months.
HUNDREDS of preclinical studies explain why: anti-parasitics exert over 12 anti-cancer mechanisms across more than 12 cancer types.
Finding an 84.4% CLINICAL BENEFIT with ivermectin and mebendazole in cancer was just the beginning...
Imaging-confirmed COMPLETE REMISSIONS of cancer using antiparasitics—WITHOUT chemo, surgery, or radiation—are soon to be published.
Stay tuned.
🚨BREAKING: Largest Real-World Study of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Tumor Regression
After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported NO EVIDENCE OF DISEASE (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization⬇️
We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.
This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).
Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.
The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.
At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):
✅ 32.8% reported no evidence of disease (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)
Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.
The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.
Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.
Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.
Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.
This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.
The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”
Follow @ZakariaMDv3 .
🚨 BREAKING — IT'S OFFICIAL: NASA's Artemis II has BROKEN the distance record for the furthest humans have ever traveled into space
248,655 miles
ONLY AMERICA could pull this off 🇺🇸
And in just hours, the Artemis crew will be going around the far side of the moon 🌖🚀